Learn more

PROBIODRUG AG

Overview
  • Total Patents
    540
  • GoodIP Patent Rank
    24,590
  • Filing trend
    ⇧ 366.0%
About

PROBIODRUG AG has a total of 540 patent applications. It increased the IP activity by 366.0%. Its first patent ever was published in 1997. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are BEIJING SHENOGEN PHARMA GROUP LTD, BIOTIE THERAPIES CORP and WYETH CO.

Patent filings per year

Chart showing PROBIODRUG AGs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Demuth Hans-Ulrich 316
#2 Heiser Ulrich 191
#3 Schilling Stephan 170
#4 Hoffmann Torsten 148
#5 Rahfeld Jens-Ulrich 81
#6 Kleinschmidt Martin 69
#7 Cynis Holger 64
#8 Buchholz Mirko 52
#9 Sommer Robert 42
#10 Niestroj Andre J 40

Latest patents

Publication Filing date Title
EP3521308A1 Humanized and de-immunized antibodies
EP3461819A1 Inhibitors of glutaminyl cyclase
GB201705263D0 Novel inhibitors
KR20180030653A Anti-pyroglutamated amyloid beta humanized antibody
WO2016097305A1 Novel method for the detection of pglu-abeta peptides
CA2904465A1 Inhibitors of glutaminyl cyclase
AU2013211539A1 Use of effectors of glutaminyl and glutamate cyclases
US2013291133A1 Mouse models carrying a knock-out mutation of the QPCTL-gene
GB201304668D0 Novel compounds
AU2012241108A1 Novel genes related to glutaminyl cyclase
WO2013024043A2 In vivo screening models for treatment of qc-related disorders
CN103561776A Radiolabelled glutaminyl cyclase inhibitors
AU2012228236A1 Diagnostic antibody assay
EP2686313A1 Benzimidazole derivatives as inhibitors of glutaminyl cyclase
AU2011265545A1 Use of effectors of glutaminyl and glutamate cyclases
EP2635675A1 Crystal structure of isoglutaminyl cyclase
IL215450D0 Pharmaceutical compositions comprising glutaminyl and glutamate cyclase inhibitors and their use for preparation of medicamentd for treatment of alzheimer's disease and down syndrome
WO2012028706A1 IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS
WO2012022804A1 Crystal structure of glutaminyl cyclase
GB201113901D0 In vivo screening models for treatment of qc-related disorders